Safety & Efficacy of Certican in Pediatric de Novo Renal Transplant Patients

Phase 3 Completed 45 enrolled Novartis Pharmaceuticals

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety and tolerability of RAD001 (Certican) administered to pediatric renal transplant recipients, and to provide additional safety data.

Timeline

Start: 2000-06
Primary completion: 2007-03
Completion: 2007-03

Publications

Results Ettenger RB, Grimm EM. Safety and efficacy of TOR inhibitors in pediatric renal transplant recipients. Am J Kidney Dis. 2001 Oct;38(4 Suppl 2):S22-8. doi: 10.1053/ajkd.2001.27838.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Everolimus	Small molecule	—	—

Indications

No indication recorded.